medigraphic.com
ISSN 1727-897X (Electronic)

2020, Number 4

<< Back Next >>

Medisur 2020; 18 (4)

Predictive value of the angiogenic test (sFlt / PIGF ratio) in hypertensive disorders of pregnancy. Perinatal results in Cienfuegos

Vázquez MVR, Torres GCJ, Torres VG

Language: Spanish
References: 27
Page: 665-674
PDF size: 320.17 Kb.


ABSTRACT

Background: Preeclampsia is the main cause of morbidity, mortality, maternal and perinatal disability, making its diagnosis and prevention important.
Objective: to validate the predictive value of the angiogenic test (sFlt / PIGF ratio) in hypertensive disorders of pregnancy.
Methods: a descriptive cross-sectional study was carried out at the Gynecology and Obstetrics Service, Dr. Gustavo Aldereguía Lima Hospital, Cienfuegos, from January 2017 to December 2018. 125 pregnant women with suspected pre-eclampsia, from the Total number of patients admitted with high blood pressure were studied. They were divided into two groups according to the diagnostic values of the Roche angiogenic test (sFlt / PIGF ratio), and perinatal results and maternal complications were compared. The Chi square statistic (p <0.05) was used and the risk ratio (95% CI) was calculated.
Results: the angiogenic test was positive more frequently in those pregnant women who developed eclampsia preeclamsia, with 90.7% vs. 9.3% in those who did not develop eclampsia preeclamsia (p = 0.000); as well as those less than 34 weeks of gestational age who developed pre-eclampsia (72%), with high sensitivity and specificity. The use of the test in the follow-up of the patients was associated with a tendency to prolong the pregnancy. Its positivity was more related to maternal, fetal and neonatal complications.
Conclusion: a positive value of the test implies an increased risk of developing preeclamsia eclampsia and maternal complications, as well as adverse perinatal results. The angiogenic test showed utility in the diagnosis and prognosis of the disease.


REFERENCES

  1. Sibai BM, Dekker G, Kupferminc M. Pre-eclampsia. The Lancet [Internet]. 2005 [citado 00/06/2018];365(9461):[aprox. 4p]. Disponible en: Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140673605179872/fulltext

  2. Zarate A, Saucedo R, Valencia J, Manuel L, Hernández M. Early disturbed placental ischemia and hypoxia creates immune alteration and vascular disorder causing preeclampsia. Arch Med Res [revista en Internet]. 2014 [citado 11/06/2019];45(7):[aprox. 3p]. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25450587

  3. Mutter W, Karumanchi A. Molecular mechanisms of preeclampsia. Microvasc Res [revista en Internet]. 2008 [citado 12/05/2019];75(1):[aprox. 16p]. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2241748/

  4. Llurba E, Crispi F, Verlohren S. Update on the pathophysiological implications and clinical role os angiogenic factors in pregnancy. Fetal Diagn Ther [revista en Internet]. 2015 [citado 12/05/2019];37(2):[aprox. 16p]. Disponible en: Disponible en: https://www.karger.com/Article/FullText/368605

  5. Jakovljevic A, Bogavac M, Zagorka Crvenkovic L, Milosevic M, Nikolic A, et al. Early pregnancy angiogenic proteins levels and pregnancy related hypertensive disorders. J Matern Fetal Neonatal Med [revista en Internet]. 2017 [citado 09/06/2019];30(5):[aprox. 3p]. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27109751

  6. Camacho K, Ventura E, Zárate A, Hernández M. Utilidad de los biomarcadores séricos involucrados en la fisiopatología de la preclampsia como predictores tempranos de diagnóstico. Perinatología y Reproducción Humana [revista en Internet]. 2018 [citado 09/06/2019];32(1):[aprox. 14p]. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S0187533718300384

  7. Zhang J, Klebanoff MA, Roberts JM. Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstet Gynecol [revista en Internet]. 2001 [citado 09/06/2019];97(2):[aprox. 3p]. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/11165592

  8. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M, et al. Predictive value of the sFlt-1:PIGF ratio in women with suspected preeclampsia. N England J Med [revista en Internet]. 2016 [citado 12/06/2019];374:[aprox. 22p]. Disponible en: Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMoa1414838

  9. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation [revista en Internet]. 2013 [citado 14/07/2019];128(19):[aprox. 20p]. Disponible en: Disponible en: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.113.003215?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed

  10. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, et al. New gestacional phase-specific cutoff values for the uses of soliuble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension [revista en Internet]. 2014 [citado 14/07/2019];63(2):[aprox. 14p]. Disponible en: Disponible en: https://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.113.01787?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed

  11. Dadelszen P, Payne B, Li J, Ansermino JM, Broughton Pipkin F, Côté A-M, et al. Prediction of adverse maternal outcomes in preeclampsia: development and validation of the full PIERS model. The Lancet [revista en Internet]. 2011 [citado 14/07/2019];377(9761):[aprox. 14p]. Disponible en: Disponible en: https://www.clinicalkey.es/#!/content/playContent/1-s2.0-S0140673610613517?returnurl=https://linkinghub.elsevier.com/retrieve/pii/S0140673610613517?showall=true&referrer=https://www.ncbi.nlm.nih.gov/

  12. Hund M, Verhagen W, Reim M, Messinger D, Does R, Stepan H. Influence of the sFlt-1/PIGF ratio on clinical decisión-making in women with suspected preeclampsia- the PreOS study protocol. Hypertens Pregnancy [revista en Internet]. 2015 [citado 14/07/2019];34(1):[aprox. 16p]. Disponible en: Disponible en: https://www.tandfonline.com/doi/full/10.3109/10641955.2014.982331

  13. Klein E, Shelmbach D, Ramoni A, Langer E, Bahlmann, Grill S, et al. Influence of the sFlt-1/PIGF ratio on clinical decision−making in woman with suspected preeclampsia. PloS ONE [revista en Internet]. 2016 [citado 14/07/2019];11(5):[aprox. 16p]. Disponible en: Disponible en: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0156013

  14. Thadhani R, Hagmann H, Shaarschmidt W, Roth B, Cingoes T, Karumanchi SA, et al. Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J Am Soc Nephrol [revista en Internet]. 2016 [citado 14/07/2019];27(3):[aprox. 20p]. Disponible en: Disponible en: https://jasn.asnjournals.org/content/27/3/903.long

  15. Huhn EA, Kreienbühl A, Hoffmann I, Schoetzau A, Lange S, Martinez de Tejada B, et al. Diagnostic Accuracy of Different Soluble fms-Like Tyrosine Kinase 1 and Placental Growth Factor Cut-Off Values in the Assessment of Preterm and Term Preeclampsia: A Gestational Age Matched Case-Control Study. Front Med (Lausanne) [revista en Internet]. 2018 [citado 10/06/2019];5:[aprox. 14p]. Disponible en: Disponible en: https://www.frontiersin.org/articles/10.3389/fmed.2018.00325/full

  16. Sovio U, Gaccioli F, Cook E, Hund M, Charnock DS, Smith GCC. Prediction of preeclampsia using the soluble fms-like tyronine kinase 1 to placental growth factor ratio: a prospective cohort study of unselected nulliparous woman. Hypertension [revista en Internet]. 2017 [citado 10/06/2019];69(4):[aprox. 14p]. Disponible en: Disponible en: https://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.116.08620?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed

  17. Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: updates in pathogenesis, definition, and guidelines. CJASN [revista en Internet]. 2016 [citado 12/05/2019];11(6):[aprox. 12p]. Disponible en: Disponible en: https://cjasn.asnjournals.org/content/11/6/1102.long

  18. Schlembach D, Hund M, Schroer A, Wolf C. Economic assessment of the use of the sFlt-1/PlGF ratio test to predict preeclampsia in Germany. BMC Health Serv Res [revista en Internet]. 2018;18(1):[aprox. 14p]. Disponible en: https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-018-3406-1

  19. Perales A, Delgado JL, Calle M de la, García JA, Escudero AI, Campillos JM, et al. sFlt-1/PIGF for early onset pre-eclampsia prediction: STEPS (Study os Early Pre.eclampsia in Spain). Ultrasound Obstet Gynecol [revista en Internet]. 2017 [citado 10/06/2019];50(3):[aprox. 12p]. Disponible en: Disponible en: https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/uog.17373

  20. Caillon H, Tardif C, Dumontet E, Winer N, Masson D. Evaluation of sFlt-1/PlGF Ratio for Predicting and Improving Clinical Management of Pre-eclampsia: Experience in a Specialized Perinatal Care Center. Ann Lab Med [revista en Internet]. 2018 [citado 10/06/2019];38(2):[aprox. 12p]. Disponible en: Disponible en: http://www.annlabmed.org/journal/view.html?volume=38&number=2&spage=95

  21. Romero JF, Álvarez MG, Encalada A, Pérez MC, Chan RG, Leaños A. Diferencia entre la concentración de factores angiogénicos en Preeclampsia e hipertensión gestacional y su relación con el resultado materno y perinatal. Ginecol Obstet Mex [revista en Internet]. 2017 [citado 10/06/2019];85(9):[aprox. 14p]. Disponible en: Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0300-90412017000900561&lng=es&nrm=iso&tlng=es

  22. Chaiworapongsa T, Romero R, Korzeniewski SJ, Pappas A, Tarca AL, Chaemsaithong P, et al. Plasma concentration of angiogenic?anti−angiogenic factors have prognosis alue inn women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Matern Fetal Neonatal Med [revista en Internet]. 2014 [citado 10/06/2019];27(2):[aprox. 14p]. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151529/

  23. Schoofs K, Grittner U, Engels T, Pape J, Denk B, Henrich W, et al. The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction. J Perinat Med [revista en Internet]. 2014 [citado 10/06/2019];42(1):[aprox. 14p]. Disponible en: Disponible en: https://www.degruyter.com/view/j/jpme.2014.42.issue-1/jpm-2013-0074/jpm-2013-0074.xml

  24. Lacunza RO, Avalos J. Restricción del crecimiento fetal y factores angiogenicos: un nuevo horizonte. Rev Peru Ginecol Obstet [revista en Internet]. 2018 [citado 10/06/2019];64(3):[aprox. 10p]. Disponible en: Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S2304-51322018000300006

  25. Leaños A, Mendez F, Ramirez K, Serrano M, Berumen G, Molina CJ, et al. Circulating angiogenic factors are related to the severity of gestational hypertension and their adverse outcomes. Medicine (Baltimore) [revista en Internet]. 2017 [citado 10/06/2019];96(4):[aprox. 14p]. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287982/

  26. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation [revista en Internet]. 2012 [citado 10/06/2019];125(7):[aprox. 16p]. Disponible en: Disponible en: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.111.054361?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed

  27. Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco C, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med [revista en Internet]. 2017 [citado 10/06/2019];377:[aprox. 16p]. Disponible en: Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMoa1704559




2020     |     www.medigraphic.com